Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box–Behnken design

References

• Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610–622.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Ong BY, Ranganath SH, Lee LY, et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 2009;30:3189–3196.
   PubMed Web of Science ®Google Scholar
• Genc DB, Canpolat C, Berrak SG. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Support Care Cancer 2012;20:385–393.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Clinical pharmacology of taxol. J Natl Cancer Inst Monogr 1993;15:25–37.
   PubMedGoogle Scholar
• Hajek R, Vorlicek J, Slavik M. Paclitaxel (taxol): a review of its antitumor activity in clinical studies minireview. Neoplasma 1996;43:141–154.
   PubMed Web of Science ®Google Scholar
• Chirio D, Gallarate M, Peira E, et al. Positive charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. Eur J Pharm Biopharm 2014;88:746–758.
   PubMed Web of Science ®Google Scholar
• Zhan C, Gu B, Xie C, et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 2010;143:136–142.
   PubMed Web of Science ®Google Scholar
• Son MJ, Song HS, Kim MH, et al. Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma. Int J Oncol 2006;28:1385–1392.
   PubMed Web of Science ®Google Scholar
• Regina A, Demeule M, Che C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008;155:185–197.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs AR, Hunt CA, et al. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 2007;124: 163–171.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Alving CR, Muggia FM. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300–306.
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171–183.
   PubMed Web of Science ®Google Scholar
• Caffo M, Raudino G, Caruso G. Nanotechnology and brain tumors drug delivery. Rec Pat Nanomed 2013;3:26–36.
   Google Scholar
• Bhaskar S S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010;7:3–28.
   PubMed Web of Science ®Google Scholar
• Gupta Y, Jain A, Jain S. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935–940.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lin PI, Wang CC. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine (Lond) 2011;6:1011–1026.
   PubMed Web of Science ®Google Scholar
• Prades R, Guerrero S, Araya E, et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 2012;33:7194–7205.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier. Eur J Pharm Biopharm 2009;71:251–256.
   PubMed Web of Science ®Google Scholar
• Yan F, Wang Y, He S, et al. Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier. J Mater Sci Mater Med 2013;24:2371–2379.
   PubMed Web of Science ®Google Scholar
• Zhang P, Hu L, Yin Q, et al. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Rel 2012;159:429–434.
   PubMed Web of Science ®Google Scholar
• Cui Y, Xu Q, Kah-Hoe Chow PKH, et al. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013;34:8511–8520.
   PubMed Web of Science ®Google Scholar
• Nornoo AO, Osborne DW, Chow DS. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis. Int J Pharmaceut 2008;349:108–116.
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharm Sci 2003;5:141–149.
   Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876–885.
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticle: in vitro and in vivo evaluation. J Control Realse 2009;133:11–17.
   PubMed Web of Science ®Google Scholar
• Yuan H, Miao J, Du YZ, et al. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008;348:137–145.
   PubMed Web of Science ®Google Scholar
• Sharma US, Balasubramanian SV, Straubinger RM. Pharmaceutical and physical properties of PTX (taxol) complexes with cyclodextrins. J Pharm Sci 1995;85:1223–1230.
   Web of Science ®Google Scholar
• Elsadek B, Graeser R, Esser N, et al. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer 2010;46:3434–3444.
   Google Scholar
• Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191–202.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Ren GF, Yuan H, et al. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf B Biointerfaces 2006;50:97–103.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 2012;11:159–167.
   PubMed Web of Science ®Google Scholar
• Emami J, Rezazadeh M, Varshosaz J, et al. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition and in vitro cytotoxicity. J Nanomaterials 2012;2012:10. Article ID 358782, pages, doi:10.1155/2012/358782.
   Web of Science ®Google Scholar
• Yang XY, Li YX, Li M, et al. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013;334:338–345.
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–133.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
   PubMed Web of Science ®Google Scholar
• Jain S, Chourasia M, Soni V, et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv 2005;12:207–215.
   PubMed Web of Science ®Google Scholar
• Patel M, Jain SK, Yadav AK, et al. Preparation and characterization of oxybenzone-loaded gelatin microspheres for enhancement of sunscreening efficacy. Drug Deliv 2006;13:323–330.
   PubMed Web of Science ®Google Scholar
• Yaowaporn S, Punsupang L, Pravara C, Ruedeekorn W. Effect of solid lipid and liquid oil ratios on properties of nanostructured lipid carriers for oral curcumin delivery. Adv Mat Res 2015;1060:62–65.
   Google Scholar
• Andalib S, Varshosaz J, Hassanzadeh F, Sadeghi H. Optimization of LDL targeted nanostructured lipid carriers of 5-FU by a full factorial design. Adv Biomed Res 2012;1:45. doi:10.4103/2277-9175.100147.
   PubMedGoogle Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles and nanostructured lipid carriers in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:S131–S155.
   PubMed Web of Science ®Google Scholar
• Pandita D, Ahuja A, Lather V, et al. Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel. Pharmazie 2011;66:171–177.
   PubMed Web of Science ®Google Scholar
• Soutu EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71–77.
   PubMed Web of Science ®Google Scholar
• Lee M, Lim S, Kim C. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007;28:2137–2146.
   PubMed Web of Science ®Google Scholar
• Teeranachaideekul V, Souto EB, Junyaprasert VB, Muller RH. Cetyl palmitate-based NLC for topical delivery of coenzyme Q(10) – development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm 2007;67:141–148.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Eskandari S, Tabakhian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol 2010;15:89–96.
   PubMed Web of Science ®Google Scholar
• Rahman H, Rasedee A, How C, et al. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomedicine 2013;8:2769–2778.
   PubMed Web of Science ®Google Scholar
• Mulik RS, Mönkkönen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010;398:190–203.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang Y, Xie X, et al. Preparation and characterization of photo-responsive cell-penetrating peptide mediated nanostructured lipid carrier. J Drug Target 2014;22:891–900.
   PubMed Web of Science ®Google Scholar
• Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008;25:289–297.
   PubMed Web of Science ®Google Scholar
• Khajavinia A, Varshosaz J, Dehkordi AJ. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 2012;23:12–23.
   Web of Science ®Google Scholar
• Soni V, Kohli DV, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 2008;16:73–78.
   PubMed Web of Science ®Google Scholar
• Changa J, Jallouli Y, Kroubi M, et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009;379:285–292.
   PubMed Web of Science ®Google Scholar
• Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrier. Biomaterials 2010;31:7748–7757.
   PubMed Web of Science ®Google Scholar